Jefferies Group’s Outlook Therapeutics OTLK Stock Holding History

Jefferies Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-560	Closed	-$25.2K	–	1912
2021 Q1	$25.2K	Buy	+560	New	+$21.4K	﹤0.01%	1540
2017 Q1	–	Sell	-614	Closed	-$296K	–	2568
2016 Q4	$296K	Hold	614	–	–	﹤0.01%	1773
2016 Q3	$418K	Sell	614 -378	-38%	-$240K	﹤0.01%	1690
2016 Q2	$540K	Buy	+992	New	+$592K	﹤0.01%	1409

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

LNC

Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Jefferies Group's OTLK Position: Q2 2021 in Review

Jefferies Group sold out of Outlook Therapeutics (OTLK) in Q2 2021, closing a stake of 560 shares — an estimated $25.2K sold.

Jefferies Group first reported a position in OTLK in Q2 2016 and held it in 4 quarters. The position peaked at $540K in Q2 2016. 63 funds tracked by Wall St. Rank hold OTLK as of Q2 2021.

Jefferies Group reported no remaining Outlook Therapeutics position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 560 Outlook Therapeutics shares in Q2 2021, an estimated $25.2K.
Jefferies Group first reported a position in Outlook Therapeutics in Q2 2016 and held it in 4 quarters.
Jefferies Group's Outlook Therapeutics position peaked at $540K in Q2 2016.
63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.